A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge
Latest Information Update: 10 Sep 2026
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Therapeutic Use
- Acronyms CHALLENGE
- Sponsors Altesa Biosciences
Most Recent Events
- 09 Sep 2026 According to Altesa BioSciences media release, the data from this study has given the ability to successfully progress into the Phase 2B CARDINAL study
- 09 Sep 2026 According to Altesa BioSciences media release, data from the trial were presented at oral presentation at the European Respiratory Society (ERS) International Congress 2026 in Barcelona, Spain.
- 08 Sep 2026 Results presented at Altesa BioSciences media release.